CTOs on the Move

Inform Genomics

www.informgenomics.com

 
Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data ...
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Carl Moor
Chief Technology Officer Profile

Similar Companies

Allied Safety Associates

Allied Safety Associates is a West Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuroVasc Technologies

NeuroVasc Technologies is a developer of mechanical thrombectomy solutions for revascularization of the brain.

Codiak Biosciences

Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have transformed our understanding of the role of exosomes in the body. We now know that these natural, cell-derived vesicles can act as a potent and safe delivery system for multiple therapeutic payloads. Recognizing the enormous potential of exosomes, Codiak is applying leading-edge translational science and rigorous drug development to build a pipeline of candidates with broad utility and the capacity to address currently “undruggable” targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas. At Codiak, we are working to create a major shift in the development of tomorrow`s medicines through scientific ambition, remarkable ingenuity and deep passion for improving patients` lives. Located in the heart of Boston`s biotechnology hub in Cambridge, Massachusetts, we are advancing a bold vision by tapping into the unique talents of a varied pool of individuals who together are achieving truly exceptional work.

Partner Therapeutics

Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients.

Cytiva

We`re the Life Sciences newcomer you already know. Cytiva is bringing our long-standing expertise to the forefront of science, to fuel research, discovery, and development with technologies, instruments, and software. We drive customer-centered innovation in 11 facilities across Asia, Europe and America from idea to commercial development stages.